By The Washington Post · Carolyn Y. Johnson
The data, presented by company news release, is ominous news for other vaccine developers. They have been scrambling to determine whether current vaccines would remain effective against the variant found in South Africa and are designing new versions in case the virus can break through the protection provided by the shot. The data is the first, highly anticipated evidence of how well a vaccine performs against variants that have drawn global concern.
The company also noted that a third of the participants in its South African trial appeared to have already been infected with the original variant of coronavirus, based on antibodies in their blood when they were vaccinated. Some of those people became infected again, according to the company, suggesting that natural immunity generated by an infection might not fully protect against the new variant.
"The South African variant is looking like it's going to be a far more complicating factor than we had hoped," said Peter Jay Hotez, dean for the National School of Tropical Medicine at Baylor College of Medicine. Hotez is developing a different coronavirus vaccine and said his team has designed one against the South African variant.
In a United Kingdom trial, where the B.1.1.7 variant has become dominant, the vaccine was 89% effective, and about half the infections were with the variant.
In a smaller and less definitive South African trial where nearly all the participants who got sick were infected with the variant first identified in that nation, the vaccine was 49% effective. But the company underscored that when looking only at people not infected with HIV, the efficacy was 60%.
"I think the constructs for all current vaccines are similar; thus, I will expect similar results," said David Ho, a professor of microbiology and immunology at Columbia University.
Laboratory tests had suggested that the immune response elicited by vaccines made by Moderna and Pfizer-BioNTech would be diminished against the variant first identified in South Africa. A 49% effective vaccine against a particularly difficult variant could still hold merit - the Food and Drug Administration had drawn the line for efficacy at 50% - but it clearly speeds up the urgency in developing a vaccine targeting the variant.
"It really signals that we really can't take it for granted that these vaccines will work as well against all variants and that we need to really have systems in place that allow us to monitor them, just like how we monitor [to make] flu vaccine every year," said Natalie Dean, an epidemiologist at the University of Florida.
This month, Novavax began developing a new version of its vaccine targeting the variant identified in South Africa and expects to select a design and begin small-scale production within weeks, chief executive Stanley Erck said, with trials to begin in the second half of the year. Novavax is one of the vaccines supported by the American government, including $1.6 billion for clinical development and a prepurchase of 100 million doses. A large phase 3 trial is ongoing in North America.
"The 60% reduced risk against COVID-19 illness in vaccinated individuals in South Africans underscores the value of this vaccine to prevent illness from the highly worrisome variant currently circulating in South Africa, and which is spreading globally," Shabir Maddi, executive director of the Vaccines and Infectious Diseases Analytics Research Unit at Wits University said in a statement. Maddi is a principal investigator in the Novavax coronavirus vaccine trial in South Africa.
"This is the first COVID-19 vaccine for which we now have objective evidence that it protects against the variant dominating in South Africa," Maddi said.
Data from a late-stage trial of a Johnson & Johnson vaccine candidate, which was partly conducted in South Africa and Brazil, is expected within days and will provide greater clarity about how the current generation of vaccines perform against variants.